Kacital

Potassium citrate, the active ingredient in Kacital, is an alkali (potassium salt) presented as an oral formulation for oral use. It is employed to alkalinize urine and to correct systemic metabolic acidosis, particularly in patients prone to calcium oxalate kidney stones, renal tubular acidosis, or certain urinary infections.

GNH USA supplies Kacital as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory documentation for global distribution.

Potassium citrate is used to modify urinary chemistry and systemic acid‑base balance in several clinical situations. - Prevention of calcium oxalate kidney stones: increases urinary citrate and pH to reduce stone formation. - Treatment of metabolic acidosis (e.g., renal tubular acidosis): supplies bicarbonate precursors that correct systemic acidemia. - Urinary alkalinization for certain infections: raises urine pH to enhance antimicrobial activity.

Potassium citrate may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal cramping, or diarrhea. - Taste alteration: metallic or salty taste. - Mild hyperkalemia: slight increase in serum potassium without symptoms.

Serious or Rare Side Effects: - Severe hyperkalemia: potentially life‑threatening elevation of serum potassium. - Metabolic alkalosis: excessive rise in systemic pH causing confusion or muscle twitching. - Allergic reaction: rash, itching, or anaphylaxis.

Potassium citrate requires careful monitoring in specific patient groups and clinical settings. - Renal function: assess kidney function before initiating therapy. - Cardiac disease: monitor potassium levels in patients with arrhythmias. - Concomitant potassium‑sparing diuretics: avoid additive hyperkalemia risk. - Pregnancy and lactation: use only if clearly needed after risk assessment. - Drug‑induced metabolic alkalosis: watch for signs in patients with chronic respiratory disease. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Potassium citrate can interact with several drug classes, influencing potassium balance and renal handling.

Major Interactions (Avoid): - ACE inhibitors or ARBs: combined use may cause significant hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): risk of dangerous potassium accumulation. - Amiloride or triamterene: additive hyperkalemia risk. - NSAIDs: may impair renal potassium excretion, increasing hyperkalemia risk. - Cyclosporine or tacrolimus: can potentiate hyperkalemia.

Moderate Interactions (Monitor Closely): - Digoxin: elevated potassium may reduce drug efficacy. - Beta‑blockers: monitor for bradycardia if hyperkalemia occurs. - Insulin therapy: hyperkalemia may blunt insulin’s glucose‑lowering effect.